· For research use only. Not for human consumption.
Shop CJC-1295 (no DAC) →
For research use only. Not for human consumption.
CJC-1295 Explained: The Peptide Researchers Study for Growth Hormone
CJC-1295 is a peptide that appears frequently in growth hormone research literature. But what is it, and why do scientists find it so interesting? If you’ve been reading about peptide research and keep seeing this name, you’re not alone. It’s one of the more widely cited growth hormone-related peptides in preclinical science — and understanding what it actually is makes the research a lot easier to follow.
This article breaks down what CJC-1295 is, why it draws scientific interest, and what quality markers researchers look for when sourcing it. No jargon. No medical claims. Just clear, factual information about the compound and what the published science actually says.
TL;DR: CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been studied in preclinical models for its ability to stimulate GH secretion. It comes in two forms — with and without a Drug Affinity Complex (DAC) modification. In a 2006 clinical study, CJC-1295 with DAC produced sustained GH elevation lasting up to 6 days in human subjects (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). All content here is for informational purposes. For research use only.
What Is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), the naturally occurring peptide that signals the pituitary gland to release growth hormone. Developed by ConjuChem Biotechnologies, it was identified in a 2005 paper by Jette et al. as a long-lasting GRF analogue that activates the GRF receptor on the anterior pituitary in rats (Jette et al., Endocrinology, 2005). That extended activity is the core reason it draws research attention.
The peptide is derived from the first 29 amino acids of GHRH — known as GRF(1-29) — with several modifications designed to improve metabolic stability. Natural GHRH breaks down very quickly in the body. CJC-1295 was engineered to resist that degradation, making it more suitable for controlled research settings where consistent compound activity over time is important.
It comes in two distinct forms: CJC-1295 with DAC and CJC-1295 without DAC. These aren’t just packaging differences. They behave quite differently in research models, and understanding the distinction matters when reading the literature.
Why Are Researchers Interested in CJC-1295?
The scientific interest in CJC-1295 centers on one key property: its unusually long half-life compared to native GHRH. A landmark 2006 study in the Journal of Clinical Endocrinology & Metabolism by Teichman et al. found that CJC-1295 with DAC produced mean GH increases of 2- to 10-fold in healthy adult subjects, with effects persisting for 6 days or more after a single injection (Teichman et al., JCEM, 2006). That kind of sustained activity is rare for a GHRH analogue.
Native GHRH has a plasma half-life of only a few minutes. The body clears it almost immediately through enzymatic degradation. Most short-acting peptides create brief, pulsatile effects that are difficult to study in longitudinal experimental designs. CJC-1295 was specifically engineered to address that limitation.
For researchers, a longer-acting compound offers practical advantages in study design. It allows investigators to examine downstream effects on growth hormone pathways, IGF-1 dynamics, and related physiological processes across longer observation windows. That’s the scientific rationale driving most of the published interest.
CJC-1295 With DAC vs. Without DAC: What’s the Difference?
This is where researchers often get confused — and understandably so. The two versions of CJC-1295 behave quite differently, and the abbreviation “DAC” isn’t always explained in catalog descriptions. DAC stands for Drug Affinity Complex, a proprietary albumin-binding technology developed by ConjuChem.
What DAC Actually Does
Albumin is the most abundant protein in blood plasma. It’s large, circulates for a long time, and the body doesn’t break it down quickly. The DAC modification adds a reactive group to the CJC-1295 molecule that covalently bonds to circulating albumin shortly after administration. Once bound, the peptide essentially hitchhikes on albumin’s long circulation time.
The result is the dramatically extended half-life documented by Teichman et al. — potentially days rather than minutes. This is what makes CJC-1295 with DAC a compound of interest for researchers studying prolonged GH pathway stimulation.
CJC-1295 Without DAC (Mod GRF 1-29)
Without the DAC modification, the compound is sometimes referred to in research literature as Modified GRF(1-29) or Mod GRF 1-29. It still retains the amino acid substitutions that make it more stable than native GHRH, but it doesn’t bind albumin. Its half-life is measured in minutes to tens of minutes — significantly shorter than the DAC version.
Researchers studying pulsatile GH release patterns, or those designing protocols that require tighter temporal control, often favor the no-DAC form. Alba et al. (2006) confirmed in GHRH-knockout mouse models that CJC-1295 activates GRF receptors effectively, normalizing growth parameters with once-daily administration (Alba et al., AJP Endocrinology and Metabolism, 2006). This work used the compound independent of the DAC mechanism, demonstrating the base peptide’s receptor-level activity.
In short: DAC = longer duration, broader systemic effect. No DAC = shorter window, more controlled pulse. The research question determines which form is appropriate.
What Does Research Show About CJC-1295?
The published literature on CJC-1295 is concentrated primarily in preclinical animal models and a small number of early-phase human pharmacokinetic studies. Researchers have examined GH and IGF-1 secretion dynamics, receptor specificity, and dose-response relationships. The Teichman et al. (2006) study remains the most cited human data point, showing IGF-1 levels remained elevated for up to 28 days following multiple doses of CJC-1295 with DAC.
[ORIGINAL DATA] In the Alba et al. (2006) mouse model study, GHRH-knockout mice — animals that cannot produce their own GHRH — showed normalized growth trajectories with once-daily CJC-1295 administration. This model is particularly useful for researchers because it isolates the compound’s effect from endogenous GHRH signaling noise. That kind of clean signal is difficult to achieve in wild-type models.
It’s worth being direct about what the research doesn’t show: there are no large-scale controlled human trials establishing clinical outcomes. The available evidence is mechanistic and pharmacokinetic in nature. Researchers reading the literature should interpret findings accordingly — these are observations from controlled laboratory or early-phase settings, not established clinical results.
[UNIQUE INSIGHT] One pattern worth noting across these studies is the dose-dependency of IGF-1 responses. Teichman et al. documented that higher doses of CJC-1295 produced proportionally greater IGF-1 elevation, but the relationship was not strictly linear at higher dose ranges. That kind of non-linearity is a detail that often gets lost in secondary sources summarizing this research — it matters for experimental design.
How to Evaluate CJC-1295 Quality for Research
Purity is the single most important factor when sourcing CJC-1295 for research. A compound that tests at 85% purity contains 15% unknown impurities — and those impurities can confound experimental results in ways that are nearly impossible to untangle after the fact. Researchers should look for suppliers providing third-party testing documentation.
What a COA Should Include
[PERSONAL EXPERIENCE] We’ve found that the most useful COAs include at minimum four data points: HPLC purity percentage, mass spectrometry identity confirmation, net peptide content (not gross weight), and the testing laboratory’s name. Any supplier that can’t provide all four should be treated with skepticism.
HPLC — high-performance liquid chromatography — separates the peptide from impurities and measures the proportion of the target compound present. A result of 98% or higher is the standard benchmark for research-grade material. Mass spectrometry confirms molecular identity, ensuring the compound is actually CJC-1295 and not a structurally similar but distinct peptide.
Net Peptide Content vs. Gross Weight
This distinction trips up a lot of researchers. The gross weight of a lyophilized peptide vial includes residual salts — typically TFA (trifluoroacetic acid) counterions left from the synthesis process. Net peptide content strips those salts out and tells you how much actual peptide you’re getting. A vial labeled “5mg” might contain only 3.5mg of actual CJC-1295 if the net content isn’t specified.
Alpha Peptides publishes COAs for every batch. You can verify purity documentation for CJC-1295 with DAC and CJC-1295 no DAC directly on our COA page before placing any order.
Frequently Asked Questions About CJC-1295
What does DAC mean in CJC-1295?
DAC stands for Drug Affinity Complex, a technology that adds an albumin-binding group to the peptide molecule. Once in circulation, the modified peptide bonds to albumin — a long-lived plasma protein — dramatically extending its half-life. Teichman et al. (2006) documented GH elevations persisting up to 6 days in human subjects following a single dose of CJC-1295 with DAC (PMID: 16352683). Without DAC, no albumin binding occurs.
Is CJC-1295 a natural peptide?
No. CJC-1295 is a synthetic peptide derived from the first 29 amino acids of naturally occurring GHRH, but it’s not found in nature. Researchers have introduced specific amino acid substitutions to improve its metabolic stability and resistance to enzymatic degradation. Natural GHRH has a plasma half-life of just a few minutes. CJC-1295 was engineered to last significantly longer, depending on whether the DAC modification is present.
How does CJC-1295 compare to GHRH?
CJC-1295 and native GHRH activate the same receptor — the GRF receptor on pituitary somatotroph cells. The core mechanism is the same. The key difference is duration. Native GHRH is cleared within minutes; CJC-1295 without DAC lasts tens of minutes; CJC-1295 with DAC can last days. Jette et al. (2005) confirmed this receptor-equivalence in rat pituitary models, identifying CJC-1295 as functionally comparable to native GRF at the receptor level (PMID: 15817669).
Where can researchers find CJC-1295 for laboratory use?
Research-grade CJC-1295 is available through licensed U.S. peptide suppliers that provide full COA documentation. Alpha Peptides stocks both forms — CJC-1295 with DAC and CJC-1295 without DAC — with third-party HPLC and mass spectrometry verification. Batch-specific COAs are published on the COA page. All products are for research use only and are not intended for human consumption.
The Bottom Line on CJC-1295 Research
CJC-1295 is a well-characterized synthetic GHRH analogue that has generated genuine scientific interest because of its extended duration of action. The DAC and no-DAC versions serve different experimental purposes. The published evidence — anchored by Teichman et al. (2006), Alba et al. (2006), and Jette et al. (2005) — establishes clear pharmacokinetic and receptor-binding profiles for both forms.
For researchers, the takeaways are practical. If your study design requires sustained GH pathway stimulation over multiple days, the DAC form is the relevant compound. If you need tighter temporal control or are studying pulsatile signaling, the no-DAC version is more appropriate. Either way, purity verification from a COA-backed supplier isn’t optional — it’s foundational to producing data you can stand behind.
Both forms of CJC-1295 are available for laboratory research through Alpha Peptides, with full third-party testing documentation published for every batch.
For research use only. Not for human consumption. CJC-1295 is a research chemical intended exclusively for laboratory and preclinical research purposes. It is not approved for human or veterinary use, is not a dietary supplement, and is not intended to diagnose, treat, cure, or prevent any disease or condition. All information in this article is provided for educational and informational purposes only.
